4.56
price down icon5.30%   -0.255
pre-market  Pre-market:  4.67   0.11   +2.41%
loading
Ardelyx Inc stock is traded at $4.56, with a volume of 4.42M. It is down -5.30% in the last 24 hours and down -11.11% over the past month. Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$4.815
Open:
$4.75
24h Volume:
4.42M
Relative Volume:
1.04
Market Cap:
$1.09B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-14.55
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-0.22%
1M Performance:
-11.11%
6M Performance:
-22.45%
1Y Performance:
-29.63%
1-Day Range:
Value
$4.54
$4.81
1-Week Range:
Value
$4.505
$4.83
52-Week Range:
Value
$4.02
$9.33

Ardelyx Inc Stock (ARDX) Company Profile

Name
Name
Ardelyx Inc
Name
Phone
510-745-7047
Name
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Name
Employee
395
Name
Twitter
@ardelyx
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ARDX's Discussions on Twitter

Compare ARDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ARDX
Ardelyx Inc
4.56 1.09B 251.85M -72.58M -63.80M -0.3134
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Ardelyx Inc Stock (ARDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-07-25 Resumed Ladenburg Thalmann Buy
Mar-04-25 Initiated BTIG Research Buy
Nov-11-24 Downgrade H.C. Wainwright Buy → Neutral
Jul-02-24 Downgrade Piper Sandler Overweight → Neutral
Apr-05-24 Initiated Leerink Partners Outperform
Dec-18-23 Initiated Raymond James Strong Buy
Sep-07-23 Initiated H.C. Wainwright Buy
Aug-25-23 Upgrade Cantor Fitzgerald Neutral → Overweight
Mar-03-23 Upgrade Wedbush Neutral → Outperform
Nov-17-22 Upgrade Piper Sandler Neutral → Overweight
May-06-22 Downgrade Cantor Fitzgerald Overweight → Neutral
Dec-01-21 Upgrade Ladenburg Thalmann Neutral → Buy
Oct-14-21 Downgrade Ladenburg Thalmann Buy → Neutral
Jul-21-21 Downgrade Jefferies Buy → Hold
Jul-20-21 Downgrade Piper Sandler Overweight → Neutral
Jul-20-21 Downgrade Wedbush Outperform → Neutral
Mar-23-21 Initiated Wedbush Outperform
Jan-06-21 Initiated Cantor Fitzgerald Overweight
Oct-20-20 Resumed Citigroup Buy
Feb-18-20 Resumed Jefferies Buy
Feb-12-20 Initiated Citigroup Buy
Feb-10-20 Initiated Cowen Outperform
Apr-08-19 Initiated Piper Jaffray Overweight
Aug-24-18 Initiated Jefferies Buy
Mar-19-18 Resumed Leerink Partners Outperform
Nov-29-17 Reiterated Citigroup Buy
Nov-22-17 Reiterated Ladenburg Thalmann Buy
Oct-17-17 Resumed Leerink Partners Outperform
Mar-31-16 Initiated Ladenburg Thalmann Buy
Mar-09-16 Initiated Cantor Fitzgerald Buy
Mar-03-16 Initiated Citigroup Buy
View All

Ardelyx Inc Stock (ARDX) Latest News

pulisher
Apr 19, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 19, 2025
pulisher
Apr 19, 2025

Lobbying Update: $620,000 of ARDELYX INC. lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 17, 2025

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 - The Manila Times

Apr 17, 2025
pulisher
Apr 17, 2025

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 | ARDX Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Ardelyx, Inc. Schedules Conference Call to Discuss Q1 2025 Financial Results and Business Update - Nasdaq

Apr 17, 2025
pulisher
Apr 16, 2025

Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey

Apr 16, 2025
pulisher
Apr 16, 2025

April 2025's Top Penny Stocks To Watch - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

Stride Announces Date for Third Quarter Fiscal Year 2025 Earnings Call - The Globe and Mail

Apr 15, 2025
pulisher
Apr 10, 2025

Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings - The Manila Times

Apr 10, 2025
pulisher
Apr 10, 2025

Ontario Teachers' Appoints Terry Hickey as Chief Technology Officer - The Globe and Mail

Apr 10, 2025
pulisher
Apr 10, 2025

Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 10, 2025

ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 08, 2025

Ardelyx CEO Michael Raab sells $191k in stock - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Ardelyx CEO Michael Raab sells $191k in stock By Investing.com - Investing.com UK

Apr 08, 2025
pulisher
Apr 07, 2025

Ardelyx stock hits 52-week low at $4.29 amid challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Ardelyx stock hits 52-week low at $4.29 amid challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 06, 2025

How To Trade (ARDX) - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 06, 2025

Levi's (LEVI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail

Apr 06, 2025
pulisher
Apr 03, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx, Inc. LawsuitARDX - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 02, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Commit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using Options - Nasdaq

Mar 31, 2025
pulisher
Mar 28, 2025

Institutional owners may take dramatic actions as Ardelyx, Inc.'s (NASDAQ:ARDX) recent 6.4% drop adds to one-year losses - simplywall.st

Mar 28, 2025
pulisher
Mar 27, 2025

How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 25, 2025

Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire

Mar 25, 2025
pulisher
Mar 20, 2025

Ardelyx Requests to Dismiss Class Action Filed by Investors - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - Marketscreener.com

Mar 20, 2025
pulisher
Mar 19, 2025

ARDELYX INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 19, 2025
pulisher
Mar 17, 2025

Trading (ARDX) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 17, 2025
pulisher
Mar 13, 2025

Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth By Investing.com - Investing.com UK

Mar 13, 2025
pulisher
Mar 13, 2025

Ardelyx honors inaugural Derek Forfang award winners - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Five Champions of Kidney Disease Advocacy Receive Groundbreaking Ardelyx Recognition - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

Insider Buying: David Mott Acquires Shares of Ardelyx Inc (ARDX) - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

8,020 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Bought by SBI Securities Co. Ltd. - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities - Investing.com India

Mar 11, 2025

Ardelyx Inc Stock (ARDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):